<DOC>
	<DOC>NCT02305615</DOC>
	<brief_summary>This prospective, multi-center, observational study will investigate the effectiveness and safety of Avastin (bevacizumab) in routine clinical practice in patients with metastatic colorectal cancer. Patients are to have initiated first-line treatment with fluoropyrimidine-based doublet chemotherapy plus Avastin according to the Avastin Summary of Product Characteristics (SmPC). Target patient enrollment is 300 in Hungary.</brief_summary>
	<brief_title>An Observational Study of Continued Avastin Plus Chemotherapy Until First Progression in Patients With Metastatic Colorectal Cancer</brief_title>
	<detailed_description />
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<criteria>Age &gt;/= 18 years Patients with histologically confirmed colorectal cancer with metastatic lesion Patients having initiated firstline treatment with fluoropyrimidinebased doublet chemotherapy plus bevacizumab according to Avastin SmPC Patients who previously received a minimum 9 cycles of 5fluorouracil (5FU)based or a minimum 6 cycles of capecitabinebased induction doublet chemotherapy (i.e. 5FU or capecitabine + oxaliplatin or irinotecan) plus bevacizumab Disease evaluation showed stable disease, progressive disease or complete response according to Response Evaluation Criteria in Solid Tumors (RECIST) within one month Able and willing to provide written informed consent and to comply with the study protocol Contraindication to receive Avastin according to the Avastin SmPC Patients who received more than 10 cycles of 5FUbased or more than 7 cycles of capecitabinebased of induction doublet chemotherapy plus bevacizumab Pregnant or lactating</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>